STAT+: FDA reverses course on Regenxbio’s childhood gene therapy after rejection
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it rejected just four months ago.
All sources
- STAT News · Center
Prism News is a free news aggregator that breaks every story into Left, Center and Right perspectives — see what each side covers, what they ignore, and how the same event gets framed differently.